目的:观察临床药师开展药学监护对维持性血液透析患者贫血治疗效果的提高作用。方法:血液透析伴肾性贫血的患者56例随机分为监护组(28例)与对照组(28例)。两组均根据相关指南进行正规治疗48周,药学监护组同时实施个体化用药监护。两组均随访48周,监测基线以及随访16,32,48周时血红蛋白(Hb)、转铁蛋白饱和度(TSAT)、血清铁蛋白(SF)等指标的计量值与达标率,比较两组各时间点促红细胞生成素(EPO)每周平均使用剂量,采用KDQOL~(TM)-36评分评估治疗前后两组患者生活质量。结果:随访16周开始,监护组Hb、TSAT及SF达标率均较治疗前显著改善并维持至随访结束(P<0.05),且明显优于同期对照组(P<0.05)。各监测时间点,两组上述指标计量值比较,差异均有统计学意义(P<0.05)。随访32周起至随访结束,两组EPO每周使用量比较,差异有统计学意义(P<0.05)。治疗后监护组各项生活质量评分与基线及对照组同时段比较,差异均有统计学意义(P<0.05)。结论:临床药师实施药学监护提高了维持性血液透析患者血红蛋白达标率,减少了EPO用量,改善了患者的生活质量。 OBJECTIVE: To observe the effect of clinical pharmacists on the treatment of anemia in patients with maintenance hemodialysis. Methods: 56 patients with hemodialysis and renal anemia were randomly divided into monitoring group (28 cases) and control group (28 cases). Both groups were treated for 48 weeks according to the relevant guidelines, while the pharmacy monitoring group also implemented individualized medication monitoring. After 48 weeks of follow-up, the measurement and the compliance rate of hemoglobin (Hb), transferrin saturation (TSAT) and serum ferritin (SF) at the baseline and follow-up of 16, The mean weekly dose of erythropoietin (EPO) at each time point was used to assess the quality of life of both groups before and after treatment with KDQOL TM -36 score. Results: The compliance rates of Hb, TSAT and SF in the guardrail group were significantly improved and maintained until the end of follow-up (P <0.05) at the 16th week of follow-up, which was significantly better than that of the control group (P <0.05). The monitoring time points, the two groups of indicators measured values, the differences were statistically significant (P <0.05). The follow-up ranged from 32 weeks to the end of follow-up. There were significant differences in EPO usage between the two groups (P <0.05). After treatment, the scores of quality of life in guardianship group were significantly different from those in baseline and control group (P <0.05). Conclusion: The implementation of pharmacy supervision by clinical pharmacists improves the compliance rate of hemoglobin in maintenance hemodialysis patients, reduces the dosage of EPO and improves the quality of life of patients.